Summary of changes in the new guidelines 2017 and policy recommendations on treatment second-line drugs and for studying preventive therapy in MDR-TB.
Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.05). ? WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the.
Consolidated treatment guidelines for drug-resistant TB (including the guidance on bedaquiline and delamanid) will be produced by WHO later in 2017.
30 oct. 2016 treatment guidelines for drug-resistant TB 2016 update
From the launch of first nationwide anti-TB drug resistance survey of India guidelines being formulated on DST guided treatment for drug resistant TB
AND LEPROSY CONTROL PROGRAM. GUIDELINES. FOR THE PROGRAMMATIC MANAGEMENT. OF DRUG-RESISTANT TUBERCULOSIS IN ZAMBIA. THIRD EDITION - 2017
Summary of changes in the new guidelines 2017 and policy recommendations on treatment second-line drugs and for studying preventive therapy in MDR-TB.
30 sept. 2018 October 2017 update ... SECTION 1:Programma c Management of drug resistant tuberculosis ... Management of contacts of MDR-TB patients.
23. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. Geneva: World Health Organization; 2016. 24.
About 8% of TB patients worldwide are estimated to have rifampicin- susceptible isoniazid-resistant TB (Hr-TB). In April 2017